CHEST Physician
-
The Medicare conversion factor: What is it and why is it punishing physicians?
This year’s final rule from CMS provided the long-expected but unwelcome news of a 2.8% cut in the 2025 Medicare conversion factor.
-
Managing central airway obstruction
New guidelines on central airway obstruction standardize diagnosis and management recommendations, emphasizing therapeutic bronchoscopy, rigid bronchoscopy, and multidisciplinary care.
-
The rising use of ketamine for airway management
Ketamine’s unique properties make it valuable for critical care treatments including airway management, sedation, and analgesia.
-
Top reads from the CHEST journal portfolio – February 2025
Read commentary of studies on oronasal CPAP for OSA, the impact of pirfenidone on IPF, and extracorporeal membrane oxygenation for high-risk PE.
-
FDA grants clearance for SIMEOX 200 for patients with chronic lung disease
The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.
-
Updated GOLD report includes significant clinical implications for COPD management
Gerard J. Criner, MD, FCCP, a member of the GOLD science committee, said one notable change was the adoption of race-neutral algorithms and equations in predictive values for lung function testing and measuring lung impairment.
-
Consequences of wildfire smoke exposure extend beyond local area
In a recent study, Mary E. Maldarelli, MD, and colleagues demonstrated that wildfires can increase health risks even from thousands of miles away.
-
Rethinking tobacco use to include all forms of nicotine delivery
Frank Leone, MD, MS, FCCP, said clinicians must reframe how they think about tobacco product use—and how to treat it.
-
New pulse oximeter recommendations make progress toward accuracy across skin tones
Aaron Baugh, MD, discussed how the recent FDA draft guidance on pulse oximeter performance testing should improve accuracy in patients with darker skin tones.
-
Expanding treatments for COPD management
Recent FDA approval of dupilumab and ensifentrine marks significant progress in therapies targeting inflammation, lung function, and symptom relief for patients with COPD.